Pfizer’s Prevnar 13 Patent Claims Wiped Out by PTAB

Drug Industry Daily
A A
In a victory for Merck, the U.S. Patent Trial and Appeal Board (PTAB) invalidated one of Pfizer’s patents for the company’s best-selling drug, the pneumonia vaccine Prevnar 13.

To View This Article:

Login

Subscribe To Drug Industry Daily